Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

Background: As in other solid tumors, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis than patients with extensive metastatic disease. Stereotactic body radiotherapy (SBRT) is now considered...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Maximilien Rogé, Yoann Pointreau, Paul Sargos, Emmanuel Meyer, Ulrike Schick, Ali Hasbini, Emmanuel Rio, Guillaume Bera, Amandine Ruffier, Magali Quivrin, Mathieu Chasseray, Igor Latorzeff, Etienne Martin, Valentine Guimas, Pascal Pommier, Thomas Leroy, Philippe Ronchin, Alexis Lepinoy, Audrey Grand, Lysian Cartier, Ossama Didas, Fabrice Denis, Vincent Libois, Audrey Blanc-Lapierre, Stéphane Supiot
Format: Artikel
Sprache:English
Veröffentlicht: Elsevier 2023-05-01
Schriftenreihe:Clinical and Translational Radiation Oncology
Schlagworte:
Prostate cancer
Oligorecurrent
Oligometastases
Stereotactic body radiotherapy
Immunotherapy
Online Zugang:http://www.sciencedirect.com/science/article/pii/S2405630823000381

Online

http://www.sciencedirect.com/science/article/pii/S2405630823000381

Ähnliche Einträge